ZA200608838B - Methods of diminishing co-abuse potential - Google Patents

Methods of diminishing co-abuse potential Download PDF

Info

Publication number: ZA200608838B
Authority: ZA; South Africa
Prior art keywords: methylphenidate; drug; abuse; alcohol; subjects
Prior art date: 2004-04-26

Application number

ZA200608838A

Other languages

English (en)

Inventor

Khetani Vikram

Faleck Herbert

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-26

Filing date

2006-10-24

Publication date

2008-05-28

2006-10-24 Application filed by Celgene Corp filed Critical Celgene Corp

2008-05-28 Publication of ZA200608838B publication Critical patent/ZA200608838B/en

Links

238000000034 method Methods 0.000 title description 13
230000003467 diminishing effect Effects 0.000 title description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 67
229960001344 methylphenidate Drugs 0.000 claims description 57
239000003814 drug Substances 0.000 claims description 48
229940079593 drug Drugs 0.000 claims description 47
235000019441 ethanol Nutrition 0.000 claims description 41
239000000126 substance Substances 0.000 claims description 20
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 16
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 13
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 2
125000005909 ethyl alcohol group Chemical group 0.000 claims 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 29
201000009032 substance abuse Diseases 0.000 description 25
230000000694 effects Effects 0.000 description 19
229960003920 cocaine Drugs 0.000 description 14
238000012360 testing method Methods 0.000 description 13
230000002411 adverse Effects 0.000 description 12
DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 10
229960001042 dexmethylphenidate Drugs 0.000 description 10
238000011260 co-administration Methods 0.000 description 9
210000003169 central nervous system Anatomy 0.000 description 8
229940005483 opioid analgesics Drugs 0.000 description 8
239000013543 active substance Substances 0.000 description 7
AIVSIRYZIBXTMM-UHFFFAOYSA-N ethylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1CCCCN1 AIVSIRYZIBXTMM-UHFFFAOYSA-N 0.000 description 6
JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000002743 euphoric effect Effects 0.000 description 5
239000000014 opioid analgesic Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000013583 drug formulation Substances 0.000 description 4
238000002483 medication Methods 0.000 description 4
229960002715 nicotine Drugs 0.000 description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
230000000506 psychotropic effect Effects 0.000 description 4
239000000021 stimulant Substances 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
201000007930 alcohol dependence Diseases 0.000 description 3
208000010877 cognitive disease Diseases 0.000 description 3
DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 description 3
208000011117 substance-related disease Diseases 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
206010015535 Euphoric mood Diseases 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229960001252 methamphetamine Drugs 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
DUGOZIWVEXMGBE-STQMWFEESA-N methyl (S)-phenyl[(S)-piperidin-2-yl]acetate Chemical compound C([C@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-STQMWFEESA-N 0.000 description 2
229960001033 methylphenidate hydrochloride Drugs 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
-1 opioids Chemical compound 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
241001539473 Euphoria Species 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000028505 alcohol-related disease Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000571 coke Substances 0.000 description 1
229940112502 concerta Drugs 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
229940125368 controlled substance Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
229940005022 metadate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
JUMYIBMBTDDLNG-UHFFFAOYSA-N methylphenidate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C(=O)OC)C1CCCC[NH2+]1 JUMYIBMBTDDLNG-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
229940099204 ritalin Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000012085 test solution Substances 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Addiction (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200608838A 2004-04-26 2006-10-24 Methods of diminishing co-abuse potential ZA200608838B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/832,210 US20050239830A1 (en)	2004-04-26	2004-04-26	Methods of diminishing co-abuse potential

Publications (1)

Publication Number	Publication Date
ZA200608838B true ZA200608838B (en)	2008-05-28

Family

ID=35137307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200608838A ZA200608838B (en)	2004-04-26	2006-10-24	Methods of diminishing co-abuse potential

Country Status (13)

Country	Link
US (4)	US20050239830A1 (fr)
EP (1)	EP1755393A4 (fr)
JP (1)	JP2007534763A (fr)
KR (2)	KR20130041359A (fr)
CN (1)	CN1946292B (fr)
AU (1)	AU2005237538B2 (fr)
BR (1)	BRPI0510325A (fr)
CA (1)	CA2564604A1 (fr)
IL (1)	IL178683A0 (fr)
MX (1)	MXPA06012348A (fr)
NZ (1)	NZ550585A (fr)
WO (1)	WO2005105087A2 (fr)
ZA (1)	ZA200608838B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090076079A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched methylphenidate

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2507631A (en) *	1944-01-19	1950-05-16	Ciba Pharm Prod Inc	Pyridine and piperidine compounds and process of making same
US2738303A (en) *	1952-07-18	1956-03-13	Smith Kline French Lab	Sympathomimetic preparation
US2957880A (en) *	1953-12-23	1960-10-25	Ciba Pharm Prod Inc	Process for the conversion of stereoisomers
US2838519A (en) *	1953-12-23	1958-06-10	Ciba Pharm Prod Inc	Process for the conversion of stereoisomers
US3048526A (en) *	1958-08-04	1962-08-07	Wander Company	Medicinal tablet
US3365365A (en) *	1965-08-09	1968-01-23	Hoffmann La Roche	Repeat action pharmaceutical compositions in the form of discrete beadlets
US4137300A (en) *	1976-08-20	1979-01-30	Ciba-Geigy Corporation	Sustained action dosage forms
US4410700A (en) *	1980-07-03	1983-10-18	The United States Of America As Represented By The Department Of Health And Human Services	Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
GB2112730B (en) *	1981-09-30	1985-12-18	Nat Res Dev	Encapsulated particles
US4728512A (en) *	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
US4904476A (en) *	1986-03-04	1990-02-27	American Home Products Corporation	Formulations providing three distinct releases
US4794001A (en) *	1986-03-04	1988-12-27	American Home Products Corporation	Formulations providing three distinct releases
US4986987A (en) *	1986-05-09	1991-01-22	Alza Corporation	Pulsed drug delivery
US4992445A (en) *	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US5114946A (en) *	1987-06-12	1992-05-19	American Cyanamid Company	Transdermal delivery of pharmaceuticals
US5236689A (en) *	1987-06-25	1993-08-17	Alza Corporation	Multi-unit delivery system
US5391381A (en) *	1987-06-25	1995-02-21	Alza Corporation	Dispenser capable of delivering plurality of drug units
US5283193A (en) *	1988-06-27	1994-02-01	Asahi Kasei Kogyo K.K.	Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor
SE509029C2 (sv) *	1988-08-16	1998-11-30	Ss Pharmaceutical Co	Långtidsverkande diklofenak-natriumpreparat
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5217718A (en) *	1989-08-18	1993-06-08	Cygnus Therapeutic Systems	Method and device for administering dexmedetomidine transdermally
US5284769A (en) *	1989-10-16	1994-02-08	Chiros Ltd.	Process for preparing a single enantiomer of a lactam using lactamase
US5362755A (en) *	1990-01-05	1994-11-08	Sepracor, Inc.	Method for treating asthma using optically pure (R)-albuterol
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
JP2558396B2 (ja) *	1990-06-28	1996-11-27	田辺製薬株式会社	放出制御型製剤
US5104899A (en) *	1990-08-13	1992-04-14	Sepracor, Inc.	Methods and compositions for treating depression using optically pure fluoxetine
US5156850A (en) *	1990-08-31	1992-10-20	Alza Corporation	Dosage form for time-varying patterns of drug delivery
US5232705A (en) *	1990-08-31	1993-08-03	Alza Corporation	Dosage form for time-varying patterns of drug delivery
JPH04230625A (ja) *	1990-12-27	1992-08-19	Standard Chem & Pharmaceut Corp Ltd	噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
US5160744A (en) *	1991-06-27	1992-11-03	Alza Corporation	Verapmil therapy
US5326570A (en) *	1991-07-23	1994-07-05	Pharmavene, Inc.	Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ATE183642T1 (de) *	1991-10-04	1999-09-15	Yoshitomi Pharmaceutical	Tablette mit verzögerter freisetzung
DE69222006T2 (de) *	1991-10-30	1998-01-22	Glaxo Group Ltd	Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) *	1992-01-10	1993-06-29	Alza Corporation	Osmotic device with delayed activation of drug delivery
US5308348A (en) *	1992-02-18	1994-05-03	Alza Corporation	Delivery devices with pulsatile effect
US5331000A (en) *	1992-03-09	1994-07-19	Sepracor Inc.	Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5299121A (en) *	1992-06-04	1994-03-29	Medscreen, Inc.	Non-prescription drug medication screening system
US5512293A (en) *	1992-07-23	1996-04-30	Alza Corporation	Oral sustained release drug delivery device
FI950467A7 (fi) *	1992-08-03	1995-03-31	Sepracor Inc	Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi
US5376384A (en) *	1992-12-23	1994-12-27	Kinaform Technology, Inc.	Delayed, sustained-release pharmaceutical preparation
JP3091618B2 (ja) *	1993-01-29	2000-09-25	四郎小林	開環重合法および開環重合用酵素触媒
JP2916978B2 (ja) *	1993-08-25	1999-07-05	エスエス製薬株式会社	放出開始制御型製剤
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
US5567441A (en) *	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
EP0840610A1 (fr) *	1995-07-14	1998-05-13	Medeva Europe Limited	Composition contenant du d-threo-methylphenidate et une autre substance
GB9514451D0 (en) *	1995-07-14	1995-09-13	Chiroscience Ltd	Sustained-release formulation
CA2223629A1 (fr) *	1995-07-14	1997-02-06	Nicholas Robert Pope	Usage therapeutique du d-threo-methylphenidate
US5837284A (en) *	1995-12-04	1998-11-17	Mehta; Atul M.	Delivery of multiple doses of medications
US5908850A (en) *	1995-12-04	1999-06-01	Celgene Corporation	Method of treating attention deficit disorders with d-threo methylphenidate
US5733756A (en) *	1996-01-05	1998-03-31	Celgene Corporation	Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5922736A (en) *	1995-12-04	1999-07-13	Celegene Corporation	Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) *	1995-12-04	2002-03-12	Celgene Corporation	Phenidate drug formulations having diminished abuse potential
US6486177B2 (en) *	1995-12-04	2002-11-26	Celgene Corporation	Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6242464B1 (en) *	1996-01-22	2001-06-05	Chiroscience Limited	Single isomer methylphenidate and resolution process
ES2187753T3 (es) *	1996-02-02	2003-06-16	Medeva Europ Ltd	Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion.
GB9604943D0 (en) *	1996-03-08	1996-05-08	Chiroscience Ltd	Resolution
GB9606417D0 (en) *	1996-03-27	1996-06-05	Chiroscience Ltd	Asymmetric cyclisation
GB9700912D0 (en) *	1997-01-17	1997-03-05	Chiroscience Ltd	Resolution
US5965734A (en) *	1997-01-31	1999-10-12	Celgene Corporation	Processes and intermediates for preparing 2-substituted piperidine stereoisomers
US6962997B1 (en) *	1997-05-22	2005-11-08	Celgene Corporation	Process and intermediates for resolving piperidyl acetamide steroisomers
US5936091A (en) *	1997-05-22	1999-08-10	Celgene Corporation	Processes and intermediates for resolving piperidyl acetamide stereoisomers
CA2348871C (fr) *	1998-11-02	2009-04-14	John G. Devane	Composition a liberation modifiee multiparticulaire
US6127385A (en) *	1999-03-04	2000-10-03	Pharmaquest Limited	Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) *	1999-03-04	2002-05-28	Pharmaquest Limited	Method of treating depression using 1-threo-methylphenidate
JP2002541092A (ja) *	1999-04-06	2002-12-03	ファーマクエスト・リミテッド	メチルフェニデートのパルス性送達のための薬学的投薬形態
US20030170181A1 (en) *	1999-04-06	2003-09-11	Midha Kamal K.	Method for preventing abuse of methylphenidate
US6221883B1 (en) *	2000-04-12	2001-04-24	Ross Baldessarini	Method of dopamine inhibition using l-threo-methylphenidate
US20020132793A1 (en) *	2000-08-28	2002-09-19	Mel Epstein	Use of methylphenidate compounds to enhance memory
AU2001285325A1 (en) *	2000-08-28	2002-03-13	Sention, Inc.	Use of threo-methylphenidate compounds to enhance memory
US6344215B1 (en) *	2000-10-27	2002-02-05	Eurand America, Inc.	Methylphenidate modified release formulations
US6359139B1 (en) *	2000-11-07	2002-03-19	Celgene Corporation	Methods for production of piperidyl acetamide stereoisomers

2004
- 2004-04-26 US US10/832,210 patent/US20050239830A1/en not_active Abandoned
2005
- 2005-04-26 EP EP05738790A patent/EP1755393A4/fr not_active Withdrawn
- 2005-04-26 CA CA002564604A patent/CA2564604A1/fr not_active Abandoned
- 2005-04-26 BR BRPI0510325-8A patent/BRPI0510325A/pt not_active IP Right Cessation
- 2005-04-26 CN CN200580013063XA patent/CN1946292B/zh not_active Expired - Fee Related
- 2005-04-26 NZ NZ550585A patent/NZ550585A/en not_active IP Right Cessation
- 2005-04-26 WO PCT/US2005/014226 patent/WO2005105087A2/fr not_active Ceased
- 2005-04-26 KR KR1020137007346A patent/KR20130041359A/ko not_active Ceased
- 2005-04-26 MX MXPA06012348A patent/MXPA06012348A/es not_active Application Discontinuation
- 2005-04-26 KR KR1020067024793A patent/KR20070004127A/ko not_active Ceased
- 2005-04-26 AU AU2005237538A patent/AU2005237538B2/en not_active Ceased
- 2005-04-26 JP JP2007510875A patent/JP2007534763A/ja active Pending
2006
- 2006-10-17 IL IL178683A patent/IL178683A0/en unknown
- 2006-10-24 ZA ZA200608838A patent/ZA200608838B/en unknown
2008
- 2008-11-12 US US12/269,471 patent/US20090062336A1/en not_active Abandoned
2012
- 2012-02-10 US US13/370,663 patent/US20120136028A1/en not_active Abandoned
2013
- 2013-02-13 US US13/765,994 patent/US20130158073A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BRPI0510325A (pt)	2007-10-23
EP1755393A2 (fr)	2007-02-28
KR20070004127A (ko)	2007-01-05
US20120136028A1 (en)	2012-05-31
JP2007534763A (ja)	2007-11-29
US20090062336A1 (en)	2009-03-05
WO2005105087A2 (fr)	2005-11-10
NZ550585A (en)	2010-09-30
CN1946292A (zh)	2007-04-11
US20050239830A1 (en)	2005-10-27
AU2005237538B2 (en)	2011-01-06
CA2564604A1 (fr)	2005-11-10
KR20130041359A (ko)	2013-04-24
EP1755393A4 (fr)	2009-05-06
IL178683A0 (en)	2007-02-11
WO2005105087A3 (fr)	2006-10-12
MXPA06012348A (es)	2007-04-19
US20130158073A1 (en)	2013-06-20
CN1946292B (zh)	2011-12-07
AU2005237538A1 (en)	2005-11-10

Publication	Publication Date	Title
RU2535046C2 (ru)	2014-12-10	Композиции для лечения злоупотребления веществами, вызывающими болезненное пристрастие, и улучшения поведения, связанного со злоупотреблениями
US20090088455A1 (en)	2009-04-02	Chronic, Bolus Adminstration Of D-Threo Methylphenidate
CA2453510C (fr)	2012-03-20	Traitement de la fatigue et des effets secondaires cognitifs associes au cancer, aux traitements contre le cancer et a la menopause au moyen de d-threo-methyphenidate
JP2002532392A (ja)	2002-10-02	エキソ−ｓ−メカミラミン製剤および治療におけるその使用
US5530013A (en)	1996-06-25	Venlafaxine in the inducement of cognition enhancement
CA2224005A1 (fr)	1996-12-19	Isomere (-) optiquement pur de norcisapride servant au traitement de troubles des voies digestives
WO2001052851A1 (fr)	2001-07-26	Methodes de traitement d'abus de substances
CN1406129A (zh)	2003-03-26	用于治疗物质滥用的方法
EP1292305B1 (fr)	2007-06-13	Utilisation du l-threo-methylphenidate pour la preparation d'un medicament pour le traitement des troubles d'rodre psychotique
AU2005237538B2 (en)	2011-01-06	Methods of diminishing co-abuse potential
US20110118310A1 (en)	2011-05-19	Treatment Using D-Threo Methylphenidate
US6713497B1 (en)	2004-03-30	Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
US12377065B2 (en)	2025-08-05	Compositions for treatment of substance use disorder
AU2001226574A1 (en)	2001-07-31	Methods for the treatment of substance abuse
EP1250136A1 (fr)	2002-10-23	Methodes de traitement d'abus de substances